These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26917691)

  • 21. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels.
    Cappell KA; Shreay S; Cao Z; Varker HV; Paoli CJ; Gitlin M
    BMC Nephrol; 2014 Jul; 15():116. PubMed ID: 25015348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.
    Locatelli F; Hannedouche T; Fishbane S; Morgan Z; Oguey D; White WB
    Clin J Am Soc Nephrol; 2019 Dec; 14(12):1701-1710. PubMed ID: 31420350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
    Winkelmayer WC; Mitani AA; Goldstein BA; Brookhart MA; Chertow GM
    JAMA Intern Med; 2014 May; 174(5):699-707. PubMed ID: 24589911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Siegel J; Jorgenson J; Johnson PE; Brophy DF; Comstock T; Feng A; Audhya P
    Am J Health Syst Pharm; 2008 Sep; 65(18):1711-9. PubMed ID: 18768997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.
    Sakaguchi Y; Hamano T; Wada A; Masakane I
    J Am Soc Nephrol; 2019 Jun; 30(6):1037-1048. PubMed ID: 31015255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM - HD Study.
    Kuo KL; Hung SC; Tseng WC; Tsai MT; Liu JS; Lin MH; Hsu CC; Tarng DC;
    J Am Heart Assoc; 2018 Aug; 7(15):e009206. PubMed ID: 30371224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time savings of weekly versus three-times-per-week administration of erythropoiesis stimulating agents in United States dialysis patients.
    Stephens JM; Emerson LC; Spry LA; Caloyeras JP; Anderson ER; Reitan JF; Ashfaq A
    Curr Med Res Opin; 2016; 32(2):313-20. PubMed ID: 26583202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.
    Strippoli GF;
    Trials; 2010 Jun; 11():70. PubMed ID: 20534124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.
    Amato L; Addis A; Saulle R; Trotta F; Mitrova Z; Davoli M
    J Nephrol; 2018 Jun; 31(3):321-332. PubMed ID: 28646375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States.
    Wright DG; Wright EC; Narva AS; Noguchi CT; Eggers PW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1822-30. PubMed ID: 26358266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease.
    Weir MR; Pergola PE; Agarwal R; Fink JC; Kopyt NP; Singh AK; Kumar J; Schmitt S; Schaffar G; Rudy A; McKay JP; Kanceva R
    Am J Nephrol; 2017; 46(5):364-370. PubMed ID: 29084409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.
    Hasegawa T; Zhao J; Fuller DS; Bieber B; Zee J; Morgenstern H; Hanafusa N; Nangaku M
    Am J Nephrol; 2017; 46(1):11-17. PubMed ID: 28564644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoiesis-stimulating agents and thrombotic events in dialysis patients.
    Suttorp MM; Hoekstra T; Ocak G; van Diepen AT; Ott I; Mittelman M; Rabelink TJ; Krediet RT; Dekker FW
    Thromb Res; 2014 Nov; 134(5):1081-6. PubMed ID: 25242244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents.
    Swaminathan S; Mor V; Mehrotra R; Trivedi AN
    Health Serv Res; 2015 Jun; 50(3):790-808. PubMed ID: 25355431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative safety of peginesatide and epoetin alfa.
    Weinhandl ED; Gilbertson DT; Collins AJ; Foley RN
    Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1003-11. PubMed ID: 24905967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
    Mc Causland FR; Claggett B; Burdmann EA; Chertow GM; Cooper ME; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; McMurray JJV; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto RD; Pfeffer MA
    Am J Kidney Dis; 2019 Mar; 73(3):309-315. PubMed ID: 30578152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A lesson from the EPO mess: stop the cost shifting.
    Amerling R
    Nephrol News Issues; 2007 Jul; 21(8):52, 54-5, 68. PubMed ID: 17688232
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.